Hanmi Group held an investor relations session and announced its 2030 mid- to long-term vision under the slogan "Again, creation and innovation." It presented four core growth pillars—obesity, anti-aging, digital healthcare, and Robotics—and set a goal of achieving a combined 5 trillion won in revenue across its affiliates by 2030.
On the 4th, the company held "Hanmi Vision Day" at the newly built "Hanmi C&C Square" near its headquarters in Songpa-gu, Seoul, and announced these plans. Professional managers, including Vice Chair Kim Jae-gyo, CEO of Hanmi Science; President Park Jae-hyun, CEO of Hanmi Pharmaceutical; Lee Dong-hwan, CEO of JVM; and Executive Director Choi In-young, head of the Hanmi Pharmaceutical R&D Center, attended and presented in person. Vice Chair Lim Joo-hyun of Hanmi Group also attended.
The company will strengthen its strategic control tower by newly establishing the Planning and Strategy Division and the Innovation Division within the holding company Hanmi Science, and reorganize its business portfolio into two tracks: Hanmi Pharmaceutical, centered on new drugs and biotech, and the non-pharmaceutical institutional sector such as JVM, Online Pharm, medical devices, and consumer healthcare.
Hanmi Pharmaceutical set a goal of achieving 2.9 trillion won in revenue in 2030 (1.9 trillion won domestic, 1 trillion won overseas) and declared a leap to become a top global pharmaceutical company. Under a strategy to launch at least one flagship product each year with annual sales of 10 billion won or more, it will grow products such as Amoprel launched this year; the GLP-1 obesity treatment efpeglanatide; and the Rollontis autoinjector.
At the same time, it will strengthen its global business by developing new products targeting items facing global patent expirations, building overseas-tailored portfolios, and expanding co-marketing partnerships with companies such as Samsung Bioepis and C. H. Boehringer Sohn AG & Co. KG.
The core direction of research and development (R&D) is an integrated research strategy on obesity and aging. In line with research trends suggesting that GLP-1 drugs can delay aging by reducing inflammation and neuroinflammation, it will advance AI- and omics-based research infrastructure and expand platforms for new targets and multi-modality (therapeutic) approaches. It will also continue developing key pipelines such as the next-generation triple agonist HM15275 and HM17321, which targets increased muscle mass, and said it plans to grow beyond oncology and obesity into an anti-aging and rejuvenation corporations by 2030.
JVM, a global corporations in automated pharmaceutical dispensing, set a goal to raise revenue to 500 billion won by 2030. It will develop 10 new products by 2028 and, centered on the robotic-arm-based dispenser Menis, pursue expanded production capacity and the establishment of a Smart Factory. It will expand packaging solution lineups such as CountMate and DOB, and, based on its AI-powered VIZEN-EX experience, apply Robotics and AI technologies across all product lines to grow into a global automation solutions corporations.
Hanmi Group aims to achieve 5 trillion won in revenue by 2030 with an average annual growth rate of 20%, and presented operating margins of 20%–25% or higher for Hanmi Science, Hanmi Pharmaceutical, and JVM. It also unveiled shareholder-friendly policies, including the introduction of a minimum dividend system and total shareholder return ratios (30% for Hanmi Science, 20% or more for Hanmi Pharmaceutical and JVM), expanded share buybacks, and enhanced stock-based compensation for employees.
Kim Jae-gyo, vice chair of Hanmi Science, said, "We will strengthen future competitiveness by reorganizing our business portfolio, further advance our capabilities in new drugs and biotech, and create new growth engines in the non-pharmaceutical business group."
Shim Byung-hwa, chief financial officer (CFO) of Hanmi Science, said, "By 2030, we will increase investment in future growth engines to raise both corporate value and shareholder value."